EMEA-001793-PIP01-15-M03
Key facts
| Active substance |
Bivalent anti-human myostatin adnectin recombinant human IgG1-Fc fusion protein (RO7239361)
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0043/2019
|
| PIP number |
EMEA-001793-PIP01-15-M03
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Duchenne muscular dystrophy
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|